These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 36730621

  • 1. Successful Treatment of Central Nervous System Involvement in Posttransplant EBV-related Lymphoproliferative Disease With Intrathecal Rituximab Therapy.
    Aslan F, Güler S, Sezgin Evim M, Aslier M, Yazici Z, Öztürk Nazlioğlu H, Meral Güneş A.
    J Pediatr Hematol Oncol; 2023 Jul 01; 45(5):e628-e630. PubMed ID: 36730621
    [Abstract] [Full Text] [Related]

  • 2. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K, Styczynski J, Krenska A, Debski R, Zajac-Spychala O, Wachowiak J, Wysocki M.
    Leuk Lymphoma; 2013 Mar 01; 54(3):503-6. PubMed ID: 22873830
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
    Su YY, Yu YF, Yan ZY, Zhao YJ, Lou JW, Xue F, Xu M, Feng Q, Ji XB, Dong XY, Wang W, Liu CF, Peng J, Liu XG.
    Diagn Pathol; 2024 Sep 07; 19(1):122. PubMed ID: 39244586
    [Abstract] [Full Text] [Related]

  • 4. Ofatumumab for Post-Transplant Lymphoproliferative Disorder.
    Seshadri M, Crane GM, Gergis U.
    Hematol Oncol Stem Cell Ther; 2022 Mar 01; 15(1):68-73. PubMed ID: 32413419
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus related post-transplant lymphoproliferative disorder prevention strategies in allogeneic hematopoietic stem cell transplantation.
    Lindsay J, Yong MK, Greenwood M, Kong DCM, Chen SCA, Rawlinson W, Slavin M.
    Rev Med Virol; 2020 Jul 01; 30(4):e2108. PubMed ID: 32301566
    [Abstract] [Full Text] [Related]

  • 6. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.
    Nozzoli C, Bartolozzi B, Guidi S, Orsi A, Vannucchi AM, Leoni F, Bosi A.
    Leuk Lymphoma; 2006 Jan 01; 47(1):167-9. PubMed ID: 16321845
    [Abstract] [Full Text] [Related]

  • 7. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C, Pasciolla M, Abramova R, Salerno D, Gomez-Arteaga A, Shore TB, Orfali N, Mayer S, Hsu J, Phillips AA, Chaekal OK, Satlin MJ, Soave R, Kodiyanplakkal RPL, Drelick A, Plate M, Besien KV.
    Transplant Cell Ther; 2023 Feb 01; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [Abstract] [Full Text] [Related]

  • 8. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M, Ito A, Maeshima AM, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T.
    Int J Hematol; 2020 Aug 01; 112(2):193-199. PubMed ID: 32472530
    [Abstract] [Full Text] [Related]

  • 9. Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
    Balaguer-Rosello A, Piñana JL, Bataller L, Montoro J, Romero S, Navarro I, Lorenzo I, Andreu R, Guerreiro M, Aguilar C, Gorriz D, Dominguez L, de la Puerta R, Gómez I, Solves P, Jarque I, Sanz MÁ, Sanz G, Sanz J.
    Transplant Cell Ther; 2021 Mar 01; 27(3):261.e1-261.e7. PubMed ID: 33781531
    [Abstract] [Full Text] [Related]

  • 10. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep 01; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 11. Successful Blinatumomab treatment in an allogeneic hematopoietic stem cell transplant recipient with EBV-related post-transplant lymphoproliferative disorder: A case report and literature review.
    Chen S, An L, Han J, Zheng X, Zhang X, Li G, Zhang Y, Cao W, Lv M, Yang D, Jiang E, Pang A, Feng S.
    Transpl Immunol; 2023 Oct 01; 80():101895. PubMed ID: 37414267
    [Abstract] [Full Text] [Related]

  • 12. Successful treatment of Rituximab-resistant Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using R-CHOP.
    Kuriyama T, Kawano N, Yamashita K, Ueda A.
    J Clin Exp Hematop; 2014 Oct 01; 54(2):149-53. PubMed ID: 25318948
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation.
    Ru Y, Chen J, Wu D.
    Eur J Haematol; 2018 Sep 01; 101(3):283-290. PubMed ID: 29949208
    [Abstract] [Full Text] [Related]

  • 14. Pre-Emptive Use of Rituximab in Epstein-Barr Virus Reactivation: Incidence, Predictive Factors, Monitoring, and Outcomes.
    Papalexandri A, Gavriilaki E, Vardi A, Kotsiou N, Demosthenous C, Constantinou N, Touloumenidou T, Zerva P, Kika F, Iskas M, Batsis I, Mallouri D, Yannaki E, Anagnostopoulos A, Sakellari I.
    Int J Mol Sci; 2023 Nov 07; 24(22):. PubMed ID: 38003218
    [Abstract] [Full Text] [Related]

  • 15. Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation.
    Work E, Gupta D, Slayton WB, Rees J, Coppola JA, Seifert R, Bleiweis MS, Jacobs JP, Peek G, Philip J, Brock A, Rivera JH, Sullivan K, Narasimhulu SS.
    Pediatr Transplant; 2024 Mar 07; 28(2):e14707. PubMed ID: 38419558
    [Abstract] [Full Text] [Related]

  • 16. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 07; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 17. Rituximab for posttransplant lymphoproliferative disorder - therapeutic, preemptive, or prophylactic?
    Storek J, Lindsay J.
    Bone Marrow Transplant; 2024 Jan 07; 59(1):6-11. PubMed ID: 38001229
    [Abstract] [Full Text] [Related]

  • 18. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY, Mo XD, Xu LP, Zhang XH, Wang Y, Liu KY, Chang YJ, Zhao XY, Huang XJ.
    Ann Hematol; 2020 Nov 07; 99(11):2649-2657. PubMed ID: 32206854
    [Abstract] [Full Text] [Related]

  • 19. Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy.
    Socié G, Barba P, Barlev A, Sanz J, García-Cadenas I, Chevallier P, Fagioli F, Guzman-Becerra N, Kumar D, Ljungman P, Pigneux A, Sadetsky N, Yáñez San Segundo L, Shadman M, Storek J, Thirumalai D, Xing B, Mohty M.
    Bone Marrow Transplant; 2024 Jan 07; 59(1):52-58. PubMed ID: 37865719
    [Abstract] [Full Text] [Related]

  • 20. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC, Medinger M, Halter JP, Baldomero H, Hirsch HH, Tzankov A, Dirnhofer S, Passweg JR, Tichelli A.
    Hematology; 2014 Jul 07; 19(5):280-5. PubMed ID: 24074746
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.